Skip to main
A fog-lit field guide to the four-peptide KLOW research blend — KPV, GHK-Cu, BPC-157 and TB-500 traced arm by arm through the tissue-repair cascade, the mechanism read first and the missing blend data named for what it is.

ABOUT THIS SITE

An editorial field guide to the four-peptide KLOW research blend

What this site is

Prescribed KLOW is a field guide to the peer-reviewed research on the KLOW peptide blend and its four components — KPV, GHK-Cu, BPC-157 and TB-500. It reads the literature one mechanism at a time; it treats no one. Nothing here is diagnosed, prescribed, or advised, and nothing is manufactured, stocked, or sold.

The name carries the word 'prescribed' as availability and status framing — a position this site occupies relative to the question of what is known — not a claim that any compound discussed here is prescribed, available by prescription, or recommended. Nothing on this site is a prescription. Nothing here is a clinical recommendation. The editorial voice reads the research as a field guide to four mechanisms, with the combination evidence — where it is absent — named plainly.

Every quantitative claim on this site cites a specific study. Every finding is attributed to the component it came from. The KLOW blend itself has never been tested in a controlled study; that absence is documented, not glossed.

This site does not link to or recommend vendors, does not list prices, and does not facilitate the acquisition of any peptide or compound.

How we handle the evidence

The KLOW component literature varies in strength. GHK-Cu has robust human topical and cosmetic data spanning decades. BPC-157 has an extensive rodent literature and a small 2025 IV safety pilot in two adults — and was placed by the FDA in category 2 of the 503A bulk-substances review. Thymosin beta-4 has well-replicated wound-model data; the TB-500 fragment is weaker evidence than the native protein. KPV's human record is limited to delivery-system pilots and an IBD-research program lineage.

We present these differences plainly, without amplifying the stronger evidence into blend-level claims and without dismissing the weaker evidence into a silence that would also misrepresent the literature. The combination rationale — four mechanistically complementary arms addressing non-overlapping cascade steps — is plausible and worth documenting. The absence of a controlled blend study is equally worth documenting.

For citations, every referenced study is listed on the KLOW references page with its DOI, PubMed URL, and component attribution.